Professional Summary
Professional Overview
Harvey Berger is the Chief Executive Officer of Kojin Therapeutics, a biopharmaceutical company focused on developing transformative treatments for cancer and other serious diseases. With over 35 years of industry experience, Berger is a renowned expert in the field of oncology drug development and has a proven track record of leading successful pharmaceutical organizations.
Experience Summary
Current Role
As CEO of Kojin Therapeutics, Berger is responsible for providing strategic vision and guidance to the company, overseeing all aspects of its operations, and driving the development of its innovative drug pipeline. Under his leadership, Kojin has secured significant funding, expanded its research and development capabilities, and made significant progress in advancing its lead candidates towards clinical trials.
Career Progression
Berger is a seasoned biotechnology executive who previously served as the Chairman and CEO of ARIAD Pharmaceuticals, a leading oncology-focused biopharmaceutical company that he founded in 1991 and led for over 25 years. During his tenure, he was instrumental in the development and commercial launch of several groundbreaking cancer therapies, including Iclusig® (ponatinib) and Alunbrig® (brigatinib). Prior to founding ARIAD, Berger held senior R&D roles at Centocor, where he played a key role in the development of the company's first FDA-approved monoclonal antibody product.
Academic Background
Berger holds a Ph.D. in Biochemistry from the University of Pennsylvania and a Bachelor of Science degree in Chemistry from the University of Chicago. He has authored numerous scientific publications and holds several patents related to his work in the field of oncology drug development.
Areas of Expertise
Berger's areas of expertise include oncology drug discovery and development, strategic business planning, commercial operations, and biopharmaceutical company leadership. He is widely recognized for his ability to translate scientific innovations into commercially successful products that improve patient outcomes.
Professional Impact
Throughout his career, Berger has been a driving force in the biopharmaceutical industry, contributing to the development of life-saving cancer treatments and fostering the growth of innovative biotechnology companies. He has served on the board of trustees of the Dana-Farber Cancer Institute and the Cameron Boyce Foundation, where he leverages his expertise to advance cancer research and support philanthropic initiatives.
Conclusion
With his extensive industry experience, deep scientific expertise, and proven leadership abilities, Harvey Berger is well-positioned to guide Kojin Therapeutics as it continues to make significant strides in the development of novel therapies for cancer and other serious diseases. His commitment to innovation and patient-centered care makes him a valuable asset to the biopharmaceutical sector.
